Physician profile
Supratim Banerjee
NPI 1942279401
$1,857.89
in general payments reported to CMS, 2019-2025
29 companies · $366 in 2025
The $366 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $94.41 · 2021: $45.76 · 2022: $261 · 2023: $577 · 2024: $292 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,235.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $197.64 | 2019-2025 | |
| Irhythm Technologies, INC. | $162.55 | 2023 | Zio Xt Patch |
| Pfizer INC. | $156.68 | 2019-2024 | |
| Boston Scientific Corporation | $126.67 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $120.09 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $118.71 | 2021-2024 | Lifevest |
| Medtronic Vascular, INC. | $116.04 | 2019-2020 | |
| Medtronic, INC. | $87.03 | 2024-2025 | Symplicity G3, Cardiosight Reader |
| Baxter Healthcare | $82.20 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Angiodynamics, INC. | $76.56 | 2023 | Alphavac |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.82 | 2023-2025 | Jardiance |
| Abbott Laboratories | $54.95 | 2021-2023 | Xience Skypoint |
| Abiomed | $54.81 | 2025 | |
| Scpharmaceuticals INC. | $50.45 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $44.69 | 2022-2025 | Farxiga |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $43.88 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Alnylam Pharmaceuticals INC. | $41.52 | 2025 | Amvuttra |
| Merck Sharp & Dohme LLC | $41.45 | 2022-2023 | Verquvo |
| Atricure, INC. | $39.24 | 2023 | |
| Impulse Dynamics (USA) INC. | $39.05 | 2024 | Optimizer |
| Daiichi Sankyo INC. | $27.34 | 2024 | Injectafer |
| Amgen INC. | $20.36 | 2023 | Repatha |
| Kiniksa Pharmaceuticals International, Plc | $19.03 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $15.29 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $13.99 | 2023 | Inpefa |
| Novo Nordisk INC | $13.63 | 2023 | |
| Bardy Diagnostics, INC. | $12.88 | 2020 | |
| Astellas Pharma US INC | $12.34 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Supratim Banerjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.